Several studies indicate that p53 tumor suppressor activity is frequently inactivated by mutations in NSCLC patients [18,19] or by interaction with MDM2, which eliminates wild-type p53 [20]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.